ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.34 ▼ -11.70 (-4.25%)HPE: $70.10 ▼ -3.36 (-4.57%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.44 ▼ -11.62 (-1.98%)PANW: $399.92 ▼ -18.86 (-4.50%)MRNA: $214.33 ▼ -10.67 (-4.74%)AAPL: $339.63 ▲ 2.99 (0.89%)AMZN: $259.90 ▼ -2.53 (-0.96%)MSFT: $540.03 ▲ 4.96 (0.93%)NVDA: $226.58 ▼ -2.70 (-1.18%)CIEN: $403.01 ▼ -46.76 (-10.40%)DDOG: $288.28 ▼ -4.98 (-1.70%)SNPS: $503.23 ▼ -6.77 (-1.33%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Agile Therapeutics, Inc.

AGRX - NASDAQ

Identifiants & Marche

Ticker AGRX
ISIN US00847L3087
CIK 0001261249
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.